Company intelligence / Profile preview
Oak Therapeutics
- Ownership
- Private
- Development stage
- Commercial
Overview
Oak Therapeutics has completed a critical Phase I milestone under an NIH/NIAID SBIR contract demonstrating bioequivalence between its proprietary isoniazid oral dissolvable strip and commercial tablets. The technology enables high-dose drug loading (>300mg), rapid dissolution (<1 minute), mucoadhesion, taste masking, and improved patient adherence—especially in children. The company is pursuing further clinical development and manufacturing scale-up.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Oral Thin Film/Oral Dissolvable Strip technology for small molecules and potentially biologicsSmall molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Oak Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oak Therapeutics.